Successful HIV
antibody testing in Uganda, begun as part of a government
education campaign that cut infection rates from 30% to 6%,
has now created more patients than the country can
care for, according to Hank McKinnell, chairman and
chief executive of U.S.-based pharmaceutical giant
Pfizer.
"Four or five
years ago, the objective was to overcome the stigma, to
get people tested and then get them into counseling and
care," said McKinnell. "We have moved past that.
Testing is now more routine in Uganda, and that is
creating its own problem. We now have more patients
than we can possibly deal with."
About 1.2 million
of Uganda's 26 million people are thought to be
HIV-positive. Health workers say more than 100,000 need
antiretroviral drugs, but most cannot access or afford
them.
McKinnell spoke
before opening an HIV clinic supported by Pfizer in the
western Ugandan town of Mbarara, roughly 186 miles from the
capital, Kampala. The $700,000 center, of which Pfizer
funded half, hopes to treat 1,000 local patients with
anti-HIV medications. Motorbike couriers will deliver
the drugs to some patients in the most remote villages.
A Ugandan
nongovernmental agency, the AIDS Support Organization, will
run the center. "The new facility in Mbarara will
boost our capacity by 100%, increasing patient medical
sessions to 50,000 in 2006 and counseling sessions to
15,000, up 6%," said Alex Coutinho, TASO's executive
director. (Reuters)